We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

A new UCLA Health study has discovered in mouse models that genes associated with repairing mismatched DNA are critical in eliciting damages to neurons that are most vulnerable in Huntington's disease ...

In a recent transaction, Alfred Sandrock, President and CEO of Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech company with a market capitalization of $240 million and strong financial health ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Kuick Research Report Highlights Ongoing Developments In Molecular Switches Application Therapeutic Targets & Drug Delivery ...